<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6173">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049243</url>
  </required_header>
  <id_info>
    <org_study_id>00006468</org_study_id>
    <nct_id>NCT01049243</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis</brief_title>
  <acronym>Vanos</acronym>
  <official_title>An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medicis Pharmaceutical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to better understand how fluocinonide cream 0.1%
      (Vanos®) works when people use it to treat atopic dermatitis for just a few days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center study. This is an open label study of fluocinonide cream 0.1%
      (Vanos™) for subjects with mild to severe atopic dermatitis with an assessment of 2 to 4 on
      the Investigator Global Assessment scale (Appendix B). Up to 20 subjects age 12 and above
      will be enrolled after providing informed consent. All subjects will receive the study
      medication, fluocinonide cream 0.1% (Vanos™). Each subject will be instructed to use
      fluocinonide cream 0.1% (Vanos™) twice daily for three consecutive days (for a total of 6
      doses). The study period will last for approximately 2 weeks. Subjects will be evaluated at
      baseline and Day 2 or 3 (as needed to achieve 6 doses), day 7 and day 14 (or end of study).
      Subjects will not apply any study drug after the 6 doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3.</measure>
    <time_frame>Baseline to 3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease severity. Based on a 6-point scale from 0 (completely clear) to 5 (very severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 14.</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Vanos</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open Label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluocinonide Cream 0.1%</intervention_name>
    <description>0.1% Cream, One Application, Twice Daily, 14 Days</description>
    <arm_group_label>Vanos</arm_group_label>
    <other_name>Vanos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female with mild to severe atopic dermatitis, 12 years of age or older, that
             agree to participate and provide written consent (and assent if applicable)

          -  Have an Investigator Global Assessment of mild to severe atopic dermatitis (IGA
             rating of 2 - 4 in the Investigator Global Assessment (Appendix B))

          -  Percentage of overall body surface are of involvement (BSA) must be ≥2%

          -  Women of child bearing potential will be allowed to participate in the study, and
             these subjects will be required to use at least one form of birth control

        Exclusion Criteria:

          -  Use within 4 weeks of baseline of systemic anti‐inflammatory medication, which may
             influence study outcome, such as systemic corticosteroids

          -  Application or use within 2 weeks of baseline of topical corticosteroid medications
             or topical anti‐inflammatory medication, which may influence study outcome

          -  Presence of a concurrent medical condition, which is determined by the investigator
             to potentially interfere with study outcomes or patient assessments

          -  Introduction of any other prescription medication, topical or systemic, for atopic
             dermatitis while participating in the study

          -  Amount of disease involvement that would require &gt;60 gm of cream in a 1 week period

          -  Subjects with known allergy or sensitivity to topical Vanos™ cream or components

          -  Pregnant women and women who are breastfeeding are to be excluded. Women of
             childbearing potential will be allowed to participate in the study, and these
             subjects will be required to use at least one form of birth control.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Feldman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 28, 2013</lastchanged_date>
  <firstreceived_date>January 12, 2010</firstreceived_date>
  <firstreceived_results_date>December 21, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest University</investigator_affiliation>
    <investigator_full_name>Steven R. Feldman</investigator_full_name>
    <investigator_title>Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Open-Label</keyword>
  <keyword>Topical</keyword>
  <keyword>Cream</keyword>
  <keyword>Eczema</keyword>
  <keyword>Vanos</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluocinonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from IRB approved advertising and the Wake Forest University Health Sciences Dermatology Clininc</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vanos</title>
          <description>Single group; 0.1% Cream, One Application, Twice Daily, 14 Days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Group</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27" lower_limit="17" upper_limit="62"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3.</title>
        <description>Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease severity. Based on a 6-point scale from 0 (completely clear) to 5 (very severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe.</description>
        <time_frame>Baseline to 3 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Single Group</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 2/3.</title>
            <description>Use of the Investigator's Global Assessment (IGA) score, a subjective scale measuring disease severity. Based on a 6-point scale from 0 (completely clear) to 5 (very severe). Defined score of 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.72" spread="0.57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Investigator Global Assessment of Atopic Dermatitis Severity From Baseline to Day 14.</title>
        <time_frame>Baseline to 14 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Group</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven Feldman, MD, PhD</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-1877</phone>
      <email>sfeldman@wfubmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
